Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer

European Urology(2024)10.1016/j.eururo.2024.09.005Source: DataRank Database

Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer is a research paper published in European Urology (2024). On theSindex it has a DataRank of 0. It has been cited 14 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access14 citations

Download PDF

Cite:

Linked data & code

geo nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 3.88)OA: greenTopics (32)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (27)

Raag Agrawal ORCID,Nicholas K. Wang ORCID,Ida Sonni ORCID,Eric V. Li ORCID,Jaron Arbet ORCID

Live enrichment

PubMed:39294048 PMC:PMC11637967 OpenAlex:https://openalex.org/W4402563197

NCI NIH HHS

Grant: P30 CA016042

NCI NIH HHS

Grant: T32 CA009213

NIGMS NIH HHS

Grant: T32 GM008042

NCI NIH HHS

Grant: P50 CA092131

NCI NIH HHS

Grant: U2C CA271894

NCI NIH HHS

Grant: P50 CA211015

NCI NIH HHS

Grant: R01 CA270108

FWCI

3.88

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://escholarship.org/content/qt9bt5w5vj/qt9bt5w5vj.pdf

publisherhttps://api.elsevier.com/content/article/PII:S0302283824025971?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0302283824025971?httpAccept=text/plain

repositoryhttps://escholarship.org/uc/item/9bt5w5vj

Fields of Study

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentImmunotherapy and Immune Responses

MeSH Terms

AgedAntigens, SurfaceHumansMaleMiddle AgedProstatic NeoplasmsBiomarkers, TumorGlutamate Carboxypeptidase IIPositron-Emission Tomography

Keywords

MedicineProstate cancerGlutamate carboxypeptidase IIProstateProstate-specific antigenAntigenPCA3CancerUrologyInternal medicineOncologyImmunologyTumorPrognosisBiomarkersGene expression profilingGene ExpressionHumansProstatic Neoplasms/pathologyProstatic Neoplasms/genetics

Sustainable Development Goals

SDG 0: Good health and well-being

Related Papers (2)

Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies

N/A

0.606DataRank · unranked

Nature Communications(2022)

co-cited

10.1038/s41467-022-34109-8

PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial

N/A

1.8DataRank · unranked

Nature Medicine(2024)

co-cited

10.1038/s41591-024-02979-8

Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer

FAIR Checklist

Authors (27)

Funding (7 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)

Related Papers (2)